Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$3.24 USD
-0.07 (-2.11%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.23 -0.01 (-0.31%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
HRTX 3.24 -0.07(-2.11%)
Will HRTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HRTX
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
HRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
United Therapeutics (UTHR) Completes Enrolment in IPF Study
New Strong Buy Stocks for July 11th
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
Other News for HRTX
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves
Heron Therapeutics initiated with bullish view at Rodman & Renshaw
Northland Securities Reaffirms Their Buy Rating on Heron Therapeutics (HRTX)
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")